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To investigate the clinical signiﬁcance of circulating angiogenic factors, especially in association with early relapse of
osteosarcoma, we quantiﬁed pre-therapeutic levels of vascular endothelial growth factor, basic ﬁbroblast growth factor and
placenta growth factor in the sera of 16 patients with osteosarcoma using an enzyme-linked immunosorbent assay. After a 1-
year follow-up, the serum level of angiogenic factors was analysed with respect to microvessel density of the biopsy specimen
and clinical disease relapse. The serum vascular endothelial growth factor levels were positively correlated with the microvessel
density with statistical signiﬁcance (P=0.004; Spearman rank correlation) and also signiﬁcantly higher in seven patients who
developed pulmonary metastasis than the remaining nine patients without detectable disease relapse (P=0.0009; The Mann–
Whitney U-test). In contrast, the serum levels of basic ﬁbroblast growth factor or placenta growth factor failed to show
signiﬁcant correlation with the microvessel density or relapse of the disease. Although there was no signiﬁcant correlation
between serum vascular endothelial growth factor levels and the tumour volume, the serum vascular endothelial growth factor
levels were signiﬁcantly higher in patients with a vascular endothelial growth factor-positive tumour than those with a vascular
endothelial growth factor-negative tumour. These ﬁndings suggest that the pre-therapeutic serum vascular endothelial growth
factor level reﬂects the angiogenic property of primary tumour and may have a predictive value on early disease relapse of
osteosarcoma.
British Journal of Cancer (2002) 86, 864–869. DOI: 10.1038/sj/bjc/6600201 www.bjcancer.com
ã 2002 Cancer Research UK
Keywords: osteosarcoma; pulmonary metastasis; angiogenesis; VEGF
Angiogenesis is an absolute requirement for the neoplastic growth
of solid tumours after they reach a critical size of 1–2 mm
3 (Folk-
man, 1995). It is also essential for tumour metastasis, facilitating
the shedding of tumour cells into surrounding blood vessels (Folk-
man, 1971, 1972, 1990). Tumour cells have been shown to secrete a
variety of angiogenic factors, including vascular endothelial growth
factor (VEGF), basic ﬁbroblast growth factor (bFGF) and placenta
growth factor (PlGF) and thereby induce the local formation of
new blood capillaries (Kandel et al, 1991; Ferrara et al, 1992;
Dvorak et al, 1995). An association between poor prognosis and
increases in vascularity has been reported in a number of tumours,
including breast carcinoma (Weidner et al, 1991), lung carcinoma
(Weidner et al, 1993), prostate carcinoma (Macchiarini et al, 1992),
cervical carcinoma (Smith-McCune and Weidner, 1994) and colon
carcinoma (Takahashi et al, 1995).
Osteosarcoma is one of the most common malignant bone
tumours. Despite recent advances in multimodality treatments
consisting of chemotherapy and wide tumour resection, pulmonary
metastasis occurs in approximately 50% of the patients with osteosar-
coma and remains a major cause of fatal outcome (Rosen et al, 1974).
Notably, such relapses with pulmonary metastasis or deaths most
likely occur during the ﬁrst year of treatment (Eilber et al, 1987; Pratt
et al, 1990; Souhami et al, 1997). Therefore, it is particularly impor-
tant for the treatment of osteosarcoma to predict the relapse of the
tumour at the early phase and customise the protocols.
We previously demonstrated that VEGF expression in osteosar-
coma tumour tissue is correlated with high microvessel density,
metastatic spread and poor prognosis (Kaya et al, 2000). Recently,
VEGF has been measured not only in tissues but also in sera by
using an enzyme-linked immunosorbent assay (ELISA), and
increased serum levels of VEFG have been reported to be correlated
with a high incidence of remote metastasis and a poor prognosis in
patients with various types of cancer (Salven et al, 1997, 1998;
Hyodo et al, 1998; Jin-no et al, 1998; Kumar et al, 1998; Landris-
cina et al, 1998; Hara et al, 1999; Oehler and Cafﬁer, 2000).
Measurement of serum VEGF levels by ELISA appears to be a more
promising procedure for quantiﬁcation than immunohistochemical
staining of tissue VEGF, although VEGF can be secreted by mega-
karyocytes and platelets other than tumour cells (Banks et al, 1998;
Webb et al, 1998; Salven et al, 1999; George et al, 2000; Lee et al,
2000).
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www.bjcancer.comIn the present study, we investigated the clinical signiﬁcance of
serum VEGF, bFGF, and PlGF in osteosarcoma in a prospective
manner, focusing on the correlation with early disease relapse
and local angiogenesis. Serum VEGF levels were corrected by plate-
let counts and the relationship of serum VEGF with tissue VEGF
expression as well as the volume of the primary tumours was also
analysed.
MATERIALS AND METHODS
Patients and sample processing
This study was approved under the institutional guidelines for the
use of human subjects in research. Between April 1998 and March
2000 (patients having presented in March 2001 could not be
followed up for 1 year, thus the study duration should end in
2000 at latest), all consecutive patients with putative diagnosis of
osteosarcoma gave informed consent to provide blood samples.
Peripheral venous blood samples were taken from these patients
before biopsy and the serum was stored at –808C until the assays
were performed. Among them, patients whose biopsy specimens
exhibited histological features compatible to osteosarcoma were
entered into the study. There were 16 patients (four women and
12 men) with the age ranging from 20 to 69 years (average 31.2
years). Nine of the tumours were located in the femur, four in
the tibia, two in the humerus and one in the pelvis. All tumours
were histologically high grade. None of the patients were associated
with Paget’s disease. Pretreatment work-up studies including palpa-
tion of the regional lymph nodes, plain chest X-rays, computed
tomography of the lung and abdomen, and bone scintigraphy
revealed the development of pulmonary metastasis in two patients.
These 16 patients were enrolled into the treatment protocol
consisting of neoadjuvant chemotherapy, wide tumour excision,
and adjuvant chemotherapy, which was basically a combination
of high-dose methotrexate, doxorubicine, cisplatin and ifosmaide.
Wide resection margin was achieved in all patients.
Early relapse was deﬁned as the detectable tumour developing in
remote sites within 1 year from the onset of the treatments. The
cases in which metastatic disease was evident at the onset of the
treatments were also deﬁned as early relapse. During a 1-year
period, patients were taken plain chest X-rays every month and
computed tomography of the lung every 3 months. Bone scintigra-
phy was taken at 1 year. Consequently, seven out of 16 patients
showed early relapse of the disease, all of them being pulmonary
metastasis. These patients were divided into two groups, the relapse
(seven patients) and no-relapse group (nine patients).
Immunohistochemical staining
The expression of VEGF and CD34 in the biopsy specimens was
determined using the avidin-biotin complex method as described
previously (Kaya et al, 2000). The primary antibody for VEGF
was a rabbit polyclonal antibody (Santa Cruz Biotechnology, Santa
Cruz, CA, USA) at 1:200 dilution, and the antibody for CD34 was
a mouse monoclonal antibody (Nichirei, Tokyo, Japan) at 1:100
dilution. The polyclonal antibody reactivity for VEGF with indivi-
dual tissue sections was considered positive if equivalent staining
was seen either in the membrane or the cytoplasm of more than
30% of the tumour cells. The number of CD34-positive vessels
was counted in four randomly selected areas of a 1-mm
2 ﬁeld
and the average number was referred as the microvessel density.
Evaluation and statistical analysis
Concentration of VEGF, bFGF and PlGF in the sera of patients
taken before biopsy was assessed by a commercially available sand-
wich ELISA (VEGF, IBL, Fujioka, Japan; bFGF and PlGF,
R&amp;D Systems, Minneapolis, MN, USA). The serum levels of
each angiogenic factor were analysed with respect to (i) the corre-
lation with microvessel density in the biopsy specimen and (ii) the
difference between the relapse group and the no-relapse group. The
serum VEGF level corrected for the number of platelet before
biopsy was also included in the analysis. In addition, the correla-
tion of the serum level of VEGF with (i) volume of the primary
tumour and (ii) expression of VEGF in the biopsy specimens were
analysed. The volume of the primary tumour was assessed upon
the longitudinal and transverse images of magnetic resonance
imaging that had been taken before biopsy, and calculated with
the following formula: p/66height6width6depth.
Spearman rank correlation test was used for the analysis of the
correlation between the serum levels of each angiogenic factor and
the microvessel density, between the serum VEGF level and the
tumour volume, and between the serum VEGF level and patient
age. The Mann–Whitney U-test was used for the comparative
analysis of each angiogenic factor levels between the relapse group
and no-relapse group and between the VEGF-positive group and
the VEGF-negative group in evaluation of the biopsy specimen.
Statistical signiﬁcance was deﬁned as P50.05.
RESULTS
Clinical parameters of 16 patients with osteosarcoma
Table 1 summarises the clinical parameters of individual patients.
The average serum levels and the 95% conﬁdence interval (CI)
of each angiogenic factor were following, VEGF; 1069.4 pg ml
71
(95% CI=551.0–2075.5 pg ml
71), bFGF; 109.7 pg ml
71 (95%
CI=61.1–196.8 pg ml
71), PlGF; 60.0 pg ml
71 (95% CI=32.2–
111.9 pg ml
71). To determine the distribution of values, means
and conﬁdence intervals on the log-transformed data have been
back-transformed to give estimates on the untransformed scale.
Two out of 16 patients had pulmonary metastases at the time of
the diagnosis and ﬁve patients relapsed with pulmonary meta-stasis
within 1 year after the onset of the treatments.
Serum angiogenic factors concentration and
microvessel density
We ﬁrst analysed the correlation between the serum levels of angio-
genic factors and the microvessel density in the biopsy specimen of
the primary tumour. As shown in Figure 1A, there was a signiﬁcant
correlation between serum VEGF level and vessel counts within the
osteosarcoma tumour (Figure 1A, P=0.004; Spearman rank correla-
tion). The correlation remained signiﬁcant when the serum VEGF
levels were corrected by platelet counts (Figure 1B, P=0.0057). In
contrast, no statistically signiﬁcant correlation was observed
between the serum PlGF or serum bFGF level and microvessel
density (Figure 1C, D, PlGF: P=0.169; bFGF: P=0.529). These
results indicate that the serum VEGF level reﬂects the microvessel
density of the primary osteosarcoma tumour. There was no corre-
lation between the serum VEGF level and patient age (P=0.898).
Serum angiogenic factors concentration and
early disease relapse
We next assessed the association between the serum angiogenic factor
levels and early relapse of osteosarcoma. The serum VEGF level was
signiﬁcantly higher in the relapse group than that in the no-relapse
group (Figure 2A, P=0.0009; Mann–Whitney U-test). The above-
mentioned mean value of serum VEGF (1069.4 pg ml
71) was chosen
as the cut-off category, yielding the sensitivity of 100% and the speci-
ﬁcity of 88.9% for detecting early disease relapse. The signiﬁcance was
retained after the serum VEGF level was corrected for platelet counts
(Figure 2B, P=0.0018). In contrast, there was no signiﬁcant differ-
ences in the serum PlGF or serum bFGF level between the two
groups (Figure 2C, D, PlGF: P=0.458; bFGF: P=0.397).
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Table 1 Patients and clinical parameters
VEGF Plt VEGF/Plt bFGF PlGF Vessel Tumour Pulmonary
Case Age Gender (pg ml
71) (10
4 pm l
71) (pg per 10
6 Plt) (pg ml
71) (pg ml
71) counts volume (cm
3) metastasis
a
1 60 M 1200.0 17.9 1.34 11.6 17.2 84 150.8 7
2 10 F 503.5 24.8 0.25 153.7 187.0 53 134.3 7
3 25 F 498.5 20.3 0.24 321.4 35.6 33 88.0 7
4 10 M 521.3 20.4 0.25 41.2 324.5 18 380.1 7
5 20 F 412.3 21.7 0.19 175.4 124.8 52 329.7 7
6 9 F 250.1 24.2 0.1 300.8 62.4 24 49.9 7
7 13 F 156.2 54.9 0.02 314.5 18.7 28 67.7 7
8 52 M 253.2 22.7 0.11 156.2 22.7 30 162.8 7
9 14 M 512.3 45.4 0.11 177.4 270.3 28 120.8 7
10 18 M 1250.0 32 0.39 17.8 15.6 88 146.5 + (10 months)
b
11 16 M 3900.0 22.5 1.73 19.4 17.8 84 628.8 + (11 months)
b
12 10 F 4700.5 17.1 2.74 82.3 127.4 49 234.4 + (0 months)
b
13 11 M 5200.6 38.5 1.35 153.7 187.0 100 143.9 + (4 months)
b
14 14 M 5700.1 25.6 2.22 162.3 27.6 98 231.7 + (5 months)
b
15 60 M 4100.3 27.6 1.48 334.5 17.9 140 189.9 + (3 months)
b
16 14 M 3200.7 27.8 1.15 169.7 262.7 85 453.3 + (0 months)
b
aRelapse with pulmonary metastasis within 1 year after the onset of the treatment.
bRelapse time with pulmonary metastasis from the onset of the
treatment.
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Figure 1 Relationship between microvessel count and serum angiogenic factors levels. Serum angiogenic factors levels against the vessel counts in 16
patients with osteosarcoma. (A) VEGF, (B) VEGF corrected for platelet counts (C) bFGF and (D) PlGF. The microvessel counts of the primary osteosar-
coma tumours correlated with serum VEGF level (P=0.004). and serum VEGF/Plt level (P=0.0057). In contrast, no statistically signiﬁcant correlation was
observed between the serum PlGF or serum bFGF level and microvessel density.
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tissue VEGF expression
To clarify whether the serum level of VEGF is dependent on the
quantitative or qualitative aspects of the primary tumour, we
assessed the relationship between the serum VEGF level and the
tumour volume as well as the tissue VEGF expression. As shown
in Figure 3A, there was no signiﬁcant correlation between the serum
VEGF level and the tumour volume. In contrast, the serum VEGF
levels were signiﬁcantly higher in patients with a VEGF-positive
tumour than those with a VEGF-negative tumour (Figure 3B,
P=0.005). There was no signiﬁcant differences in the tumour volume
between the relapse and no-relapse groups (Figure 3C, P=0.064).
DISCUSSION
In the current study, we have found that increased pre-therapeutic
serum levels of VEGF in 16 patients with osteosarcoma correlate
with (i) high microvessel density of the primary tumour, (ii) relapse
with pulmonary metastasis during the ﬁrst year of treatment, and
(iii) positive expression of tissue VEGF. In contrast, serum bFGF
or PlGF failed to show a positive correlation with the microvessel
density or a signiﬁcant association with relapse of the disease. These
ﬁndings suggest that the pre-therapeutic serum VEGF levels reﬂect
the angiogenic property of primary tumour and may have a predic-
tive value on early disease relapse of osteosarcoma.
It is known that the majority of patients with osteosarcoma have
micrometastatic diseases on initial presentation (Goorin et al, 1985;
Eliber and Rosen, 1989), leading to early clinical relapse of the
tumour in approximately 50% of the patients despite introduction
of neoadjuvant chemotherapy (Rosen et al, 1974; Eilber et al, 1987;
Pratt et al, 1990; Souhami et al, 1997). This fact implies the impor-
tance of identifying patients at high risk of relapse early in the
course of disease, to whom a more intense chemotherapy or other
therapeutic modalities are applied. Accordingly, an attempt has
been made to switch the chemotherapy regimen into an alternative
one with intensiﬁcation of reagents before surgery in patients who
exhibit progressive disease during neoadjuvant chemotherapy
(Wada et al, 1996; Meyer et al, 2001). It appears to be more ideal
to ﬁnd a biologic proﬁle of osteosarcoma, available at diagnosis,
which is linked to relapse of the disease and poor prognosis.
Measurement of pre-therapeutic serum VEGF is advantageous for
its simple and rapid procedure and provides a prognostic value
consistent with immunohistochemical (Kaya et al, 2000) or genet-
ical detection (Lee et al, 1999) of tissue VEGF in biopsy specimens.
Recently, expression of VEGF has been examined in malignant
bone and soft tissue tumours other than osteosarcoma and there have
been contradictory results. Whereas Yudoh et al (2001) found a
signiﬁcant correlation between tissue VEGF expression and poor
prognosis in soft tissue sarcomas, Chao et al (2001) and Kuhnen et
al (2000) failed to ﬁnd such signiﬁcance. Kawauchi et al (1999) docu-
mented no prognostic signiﬁcance of VEGF expression in synovial
sarcoma. In chondrosarcomas, expression of VEGF was associated
the histological grade (Ayala et al, 2000). Because histological grade
is the most important, generally accepted, prognostic factor in soft
tissue sarcomas as well as in chondrosarcoma, the predictive value
of VEGF may beless important in those tumours than that in conven-
tional osteosarcomas that are exclusively high grade in histology.
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Figure 2 Relationship between the disease relapse and serum concentration of each angiogenic factor. The differences in each angiogenic factor level
between the no-relapse and relapse group. The serum levels of VEGF and the serum levels of VEGF corrected for the count of platelet were signiﬁcantly
higher in the patients of the relapse group. In contrast, there was no signiﬁcant differences in the serum PlGF or serum bFGF level between the two groups.
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show a signiﬁcant correlation with the microvessel density or associa-
tion with relapse of the disease, emphasising the critical role of VEGF
in angiogenesis of osteosarcoma. Such a predominant role of VEGF
than other angiogenic factors has been shown by comparative studies
in gastric carcinoma (Yoshikawa et al, 2000) and renal cell carcinoma
(Edgren et al, 1999). On the other hand, bFGF but not VEGF has
shown prognostic relevance for head and neck cancer, suggesting that
the dependency of tumoral neovascularisation on angiogenic factors
may vary between tumour types (Dietz et al, 2000).
Since the values of serum VEGF in drawn blood samples can be
increased during clot formation (Banks et al, 1998; Webb et al,
1998; Salven et al, 1999; George et al, 2000; Lee et al, 2000), it is possi-
ble that increased serum VEGF levels seen in the present study may
not be a true reﬂection of tumour angiogenic activity. However,
correction of the VEGF levels by platelet counts did not impair the
signiﬁcance in correlation with microvessel density or association
with early disease relapse. In addition, the increased serum VEGF
levels reﬂected well with tissue expression of VEGF protein within
the primary tumour. It should be noted, in this regard, that one
patient exhibited high serum VEGF despite negative tissue VEGF
expression. In this patient, we have observed signiﬁcant reduction
of serum VEGF after removal of the primary tumour (Kaya M et
al, unpublished observation), suggesting a problem in tissue staining
procedure or the quality of the tissue sections examined.
Because of the rarity of osteosarcoma, there is a difﬁculty in
designing a prospective study with a large number of participants.
Although the median value of serum VEGF (1069.4 pg ml
71)
chosen as the cut-off category yielded the sensitivity of 100%
and the speciﬁcity of 88.9% for detecting early disease relapse,
generalisation of this value requires additional prospective studies
with large sample size as well as the sequential analysis of serum
VEGF levels in individual patients at various points including the
timing of disease relapse. In this sense, the present analysis serves
as a pilot study with the strength in its prospective design and
the uniformity of participants and treatment protocol.
In conclusion, the present study revealed the clinical signiﬁcance
of pre-therapeutic serum VEGF levels that were signiﬁcantly higher
in patients with osteosarcoma who relapsed during the ﬁrst year of
treatment, and also provided the basis to establish the anti-angio-
genic principles for further therapy targeting patients at high risk
of angiogenesis-dependent relapse of osteosarcoma.
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